I did type in AMBS in my browser once and it was listed with 4 other stocks on a stupid penny stock alert. So was INO. So was CPRX. So was NVIV... The list goes on and on. They just look for momentum. MANF has real science behind it just like GDNF. Look what happened to Synergen when Amgen bought them out for $260 million. I don't know which is better of the two, but from the science available right now (all preclinical) they look about the same.
So give AMBS a 260 million market cap based on precedence is fair. Now take in inflation from that buyout in 1993, how would that price out. 1% a year minimum inflation for 20 years. That's $300 million right there. Add in Lympro (hopefully) and we'll see what a 800 million market cap stock does to a stock that is trading less than 7 cents. Best to all.
I guess you can't post 4 greater signs in a row, last statement should read Zerenex 4 greater signs SFP... $15-16 is too low
Deliveryman, This is INOs standard technology... DNA vaccine for HIV. Has not been PRed yet, but it likely will be PRed by the NIH, not INO. INO just gave them the DNA vaccine and the electroporation device to combine with this rubella based vaccine. This is likely the approach that will work better than the recently PR'ed HIV monoclonal antibody for HIV.
And I would say at least 50% of biomed labs in the molecular biology/immunology/microbiology field in the country use DNA plasmids to over-express or knock down expression of genes. Its tedious, but it is pretty simple if you follow the steps. Three weeks ago was the last time I did it. I got two plasmids from Vanderbilt (one expressing the proteins to make a virus that has a mutant CREB protein (a transcription factor) and a helper plasmid that without it, the virus will not be made. I put each plasmid into a different vial of E. coli. After 24 hours of culture, you lyse the bacteria in a special solution to pull out the plasmids only (Qiagen has a kit for this). Then I used lipofectamine (instead of electroporation) to get the plasmids into the HEK cells. These cells then made the virus that expressed the mutant protein. I took the media from these cells, and put it on primary macrophages while spinning them in a centrifuge for 2 hours. That's it. The virus infected the macrophages and they started expressing the mutant protein to inactivate CREB. Then I was able to see the role of CREB in response to bacterial endotoxin treatment.
INO is not using complex technology. Like I said, its tedious but fairly simple as long as you have the plasmids and a way to get the plasmids into cells. That's how I understand what INOs new PR was about. My lab (and hundreds if not thousands of labs) whether they are in the DNA field or not, does it all the time. In this era of molecular medicine, overexpression and knockdown experiments are an integral part of medical research. I am far from an expert in it, but you just follow the protocol, and it works
So put me on ignore. I am not a psychiatrist but I am a rational person, and I can say from some of your posts below, you need to get help. I have owned this stock since May, and it was the 3rd stock that I bought. I have never attempted to mislead anyone.
You are on ignore after this. I am telling you the statements you usually make are great, but this one was misleading in a sea of misleading statements (intentionally by the shorts, and unintentionally by longs) that were going around by shorts and people who don't understand the science behind this particular PR. I know you are a passionate investor, and you had absolutely zero intention of being misleading. I also know Roman was not trying to be misleading in another thread he started about monoclonal antibodies, but if I am hypothetically a new investor and I see claims made by longs that aren't exactly true, that keep getting bumped up, I may think someone is trying to pull the wool over my eyes, and I may cut tail and run. That's all I am saying.
I was short in my responses to you both, and I apologize about that, but it was because I had a few minutes at work, and I wanted to check on Ino because it is a distraction from the daily grind. I posted my take on several studies that have not been released yet that Kyle pointed out, that could be very, very good news for INO for future partnerships, etc. I have been short in general because I work hard all day, and then I come home and I write grants. I have gotten 1-3 hours of sleep the past 2 weeks. I have a 3 year old and a 1 year old, whom I just helped my wife put to bed, so my patience is a little thin, and I have to be short because I have too much on my plate.
About the PR, I will bump the threads about it that Kyle and I discussed when the paper came out. But the skinny is this isn't a "vaccine" at all. Its getting a cell to overexpress a protein. The protein, here just happens to be an HIV antibody. See erg0t250s post below. He gets it.
And I did explain the PR in two threads last night. I saw it got bumped up a couple of times today
I was working. Sorry I couldn't join you earlier. I come out before and after hours.
Also I never claimed it was difficult to grasp for me. I said it was difficult to grasp in general. Like I've said before, I use DNA plasmids in the lab to express proteins all the time. The technology has been around since the 1980s. Inovio is smarter than me because they realized that they can use it to (eventually) save millions of lives through vaccines. That's why I've invested in them.
Anyway, I do wish you well.
Wow dude. Calm down. This is quite possibly the most ridiculous post I have seen. I am glad you feel that your calling is to be the protector of a message board on the internet in the magical world you live in, but there might be some psychological issues going on right there. If you can pick out one of my posts where I slighted you in any way (besides the one above-where I didn't name call, I just disagreed with the post because the PR was confusing enough as it is). In fact I recall numerous posts where I mention you as one of the people who post good things about this stock.
I'm not a psychologist. And I never claim to have been. I was sincerely apologizing to you. If you don't accept it, fine, There's nothing else I can do. Now go back to typing a million posts a day about how you're He Man the defender of the Universe. By the Powers of Gray Scull... Lol.
Delivery, if I ever offended you before, I am sorry. I don't take swipes at people that have a sincere interest in the same things I do (or I try not to, at least). It sounded misleading to me but I see where you are coming from.
The majority of the problem with this technology is that it is very difficult to grasp, and I don't think they should have put a PR about it at all. I think that is why the stock price dropped after they released it. Many people think that what they did was fuse a plasmid to a monoclonal antibody, and others think the company is directly making monoclonal antibodies to HIV.
Then, when I saw this post, I thought it may confuse even more people with regards to this technology.
As far as your comment about mice, and apes. I know its gonna happen to move forward, but is it even necessary? Basically some people infected with HIV for a long time are already making these antibodies to begin with. That's how they were discovered. They just got the DNA sequence from the B cells making the protective antibody, put it into a plasmid, and voila. Now anybody can make anti-HIV antibodies. We already know the protein product is safe because these HIV infected people have lots of it floating in their blood already and they seem to be fine (in fact they are not as sick as HIV infected people that do not have this antibody floating around). Why do we need to inject it into mice and apes, if its already known to be produced and safe in humans.
Anyway, sorry that I offended you. That was not my goal.
I don't understand this. You can make what, 1 maybe 1.5 pennies per share shorting this stock if you're lucky and if it goes down. But you can lose your home if the Lympro data and partnership happen. If they get a PR for MANF at the same time, and this stock goes up to 0.60-0.70 cents, and you're shorting the hundreds of thousands you need to so that you can see any profit shorting a 7 cent stock, well you just lost a million dollars. I'll take my chances at Vegas before shorting this stock, because there I will at least have fun instead of sitting in front of my computer all day hoping today's the day it doesn't jump 16.86% and making sure I get it right when it falls that 3/4 of a penny that will make me a couple hundred bucks.
That enhanced plasmid technology, if it can be permanently incorporated into DNA, and dosing can be optimized can cure virtually any autoimmune disease that we know the pathogenic mechanism of disease. Such as Familial Mediterranean Fever (IL-1b). Or psoriasis (IL-17, IL-23, or TNF). Just think, you permanently make their muscle make the enbrel or stellara or humira or anakinra, and they won't need injections every two weeks.
1) Dr. Kim has 18 million shares or something like that. He already made 40 million off of his shares alone. I agree though, why aren't other insiders buying?
2) Electroporation is just a technique using electricity. The Cyberknife is a self cauterizing electroporation tool used in surgeries and has already been approved in surgeries where tissue is exposed much longer to "electroporation" than during the vaccination.
Electroporation can't cause a permanent mutation, it just opens up pores in cell membranes to allow larger molecules to pass through. The only way to get "permanent mutations" is if you use a virus vector (not a naked plasmid like Inovio uses) to randomly and permanently incorporate into the genome resulting in stable expression of the gene of interest. This was the problem with the first gene therapy trials using retroviruses to express adenosine deaminase for severe combined immunodeficiency in children. Because they used viruses that randomly incorporated into the genome, these first patients developed lymphoma either because the gene of interest got inserted into a tumor suppression gene (inactivating it) or leading to a permanently activated oncogene.
Inovio's technology is a form of transient transfection and eventually the plasmid vector that passes through the cell and nuclear membrane gets spit out and lost from the cell (this usually happens when the cell divides) because the plasmid never gets incorporated into the genome. I've explained this multiple times. Who knows, the FDA has been dumb before, but really scientifically there is no way to get a plasmid to permanently incorporate into the genome.
There are now smart/safe virus vectors that can only incorporate into one locus of a particular (not important) gene. If Inovio can use one of these viral vectors to get the new HIV enhanced plasmid technology that produces the monoclonal antibody which neutralizes HIV, then that is the vaccine for HIV. That is 10-20 years away.
To get rid of Staph infections, you need neutrophils and T cells. While INO generates T cell responses, its not the right kind of T cell responses that is needed to kill staph infections. INO vaccines generate Th1 immunity. This kills intracellular bacteria whereas staph is mainly extracellular (except in neutrophils and macrophages that are killing the bacteria). It was thought that Th2 immunity is what you needed to kill staph because that targets extracellular parasites and bacteria.
However new evidence suggests that Th2 immunity isn't the one that kills staph. It is thought that a newly described T cell called a Th17 cell because it makes IL-17. IL-17 is needed to attract neutrophils and in mice that can't make Th17 cells they have a really tough time killing staph.
So, don't be surprised if INO has a vaccine that contains an IL-23 expressing plasmid instead of IL-12 to prime the immune system to kill staph. IL-23 is what dendritic cells and macrophages make to generate a Th17 response in T cells.
The more you know. Ding
2) This is huge. I repeat huge. They will not use this vaccine (solo) for HIV, but the results showing therapeutic anti-HIV responses in humans is integral for the success of this INO program. The results are very near publication. Don't despair that they will not move forward with this vaccine. The reason I say that this vaccine will not be used solo, is they already have a better vaccine (one that also targets B cell antigens to make antibodies against HIV), since this vaccine only targets T cell antigens. This was a proof of concept vaccine as nobody has shown any effective T cell responses against HIV. Nobody.
3) We already know what Roche thinks of this vaccine, so my input is not needed here.
4) The most important part of their whole program. Transdermal patch vaccines. The Ron Popeil of vaccines: Set it and forget it. This is what the military is working on with INO. I am a troop going to Congo, I need my Ebola, Marburg vaccines please. Slap it on his arm and he's good to go. Also, you can put a Lightning McQueen sticker on it and give it to a kid and say its a cool sticker. Meanwhile, he's getting his flu vaccine, Hep B vaccine, MMR vaccine, and chickenpox vaccine. Much less painful than an intramuscular shot with an electric jolt :-)
5) RSV: very needed vaccine, but they won't be first to market. NVAX will be there first and they are getting pretty robust vaccine responses in their own right.
6) MRSA: MRSA incidence is going down, but it is still a serious problem. The problem is there are different strains of MRSA that use different virulence factors. Some MRSA strains cause superficial infections (impetigo) and never go deep. Some cause abscesses. Some can cause blood infections resulting in sepsis. We are still learning the virulence factors. This will require some thought. All vaccines have failed to date because the antibodies made by people after the vaccine don't neutralize the bug. The kicker: see my next post...